Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2001
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EA01
|
| gptkbp:brand |
gptkb:Gleevec
|
| gptkbp:CASNumber |
152459-95-5
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:discoveredBy |
gptkb:Brian_Druker
gptkb:Nicholas_Lydon |
| gptkbp:genericName |
gptkb:imatinib
|
| gptkbp:hasMolecularFormula |
C29H31N7O
|
| https://www.w3.org/2000/01/rdf-schema#label |
STI571
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits BCR-ABL tyrosine kinase
inhibits PDGFR inhibits c-KIT |
| gptkbp:molecularWeight |
493.6 g/mol
|
| gptkbp:sideEffect |
nausea
edema rash muscle cramps |
| gptkbp:usedFor |
gptkb:gastrointestinal_stromal_tumor
gptkb:chronic_myeloid_leukemia |
| gptkbp:bfsParent |
gptkb:ChEMBL651
gptkb:136434-34-9 |
| gptkbp:bfsLayer |
7
|